Literature DB >> 34014536

The Heterogeneity of Breast Cancer Metabolism.

Jessica Tan1, Anne Le2,3.   

Abstract

Despite advances in screening, therapy, and surveillance that have improved patient survival rates, breast cancer is still the most commonly diagnosed cancer and the second leading cause of cancer mortality among women [1]. Breast cancer is a highly heterogeneous disease rooted in a genetic basis, influenced by extrinsic stimuli, and reflected in clinical behavior. The diversity of breast cancer hormone receptor status and the expression of surface molecules have guided therapy decisions for decades; however, subtype-specific treatment often yields diverse responses due to varying tumor evolution and malignant potential. Although the mechanisms behind breast cancer heterogeneity is not well understood, available evidence suggests that studying breast cancer metabolism has the potential to provide valuable insights into the causes of these variations as well as viable targets for intervention.

Entities:  

Keywords:  Breast cancer; Choline metabolism; Estrogen metabolism; Estrogen receptor status; Glycolytic upregulation; Intratumoral heterogeneity; Metabolic adaptivity; Metabolic fingerprint; Serine biosynthesis

Mesh:

Substances:

Year:  2021        PMID: 34014536     DOI: 10.1007/978-3-030-65768-0_6

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  58 in total

1.  IL-21 promotes the production of anti-DNA IgG but is dispensable for kidney damage in lyn-/- mice.

Authors:  Toni Gutierrez; Jessica M Mayeux; Sterling B Ortega; Nitin J Karandikar; Quan-Zhen Li; Dinesh Rakheja; Xin J Zhou; Anne B Satterthwaite
Journal:  Eur J Immunol       Date:  2012-12-18       Impact factor: 5.532

2.  Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer.

Authors:  Amira Elgogary; Qingguo Xu; Brad Poore; Jesse Alt; Sarah C Zimmermann; Liang Zhao; Jie Fu; Baiwei Chen; Shiyu Xia; Yanfei Liu; Marc Neisser; Christopher Nguyen; Ramon Lee; Joshua K Park; Juvenal Reyes; Thomas Hartung; Camilo Rojas; Rana Rais; Takashi Tsukamoto; Gregg L Semenza; Justin Hanes; Barbara S Slusher; Anne Le
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-24       Impact factor: 11.205

3.  Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function.

Authors:  N V Rajeshkumar; Prasanta Dutta; Shinichi Yabuuchi; Roeland F de Wilde; Gary V Martinez; Anne Le; Jurre J Kamphorst; Joshua D Rabinowitz; Sanjay K Jain; Manuel Hidalgo; Chi V Dang; Robert J Gillies; Anirban Maitra
Journal:  Cancer Res       Date:  2015-06-25       Impact factor: 12.701

Review 4.  Why do cancers have high aerobic glycolysis?

Authors:  Robert A Gatenby; Robert J Gillies
Journal:  Nat Rev Cancer       Date:  2004-11       Impact factor: 60.716

5.  Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression.

Authors:  Anne Le; Charles R Cooper; Arvin M Gouw; Ramani Dinavahi; Anirban Maitra; Lorraine M Deck; Robert E Royer; David L Vander Jagt; Gregg L Semenza; Chi V Dang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-19       Impact factor: 11.205

6.  Genetic alterations and oncogenic pathways associated with breast cancer subtypes.

Authors:  Xiaolan Hu; Howard M Stern; Lin Ge; Carol O'Brien; Lauren Haydu; Cynthia D Honchell; Peter M Haverty; Brock A Peters; Thomas D Wu; Lukas C Amler; John Chant; David Stokoe; Mark R Lackner; Guy Cavet
Journal:  Mol Cancer Res       Date:  2009-04       Impact factor: 5.852

7.  Evaluation of LDH-A and glutaminase inhibition in vivo by hyperpolarized 13C-pyruvate magnetic resonance spectroscopy of tumors.

Authors:  Prasanta Dutta; Anne Le; David L Vander Jagt; Takashi Tsukamoto; Gary V Martinez; Chi V Dang; Robert J Gillies
Journal:  Cancer Res       Date:  2013-05-30       Impact factor: 12.701

8.  BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies.

Authors:  Ubaldo E Martinez-Outschoorn; Renee Balliet; Zhao Lin; Diana Whitaker-Menezes; Ruth C Birbe; Alessandro Bombonati; Stephanos Pavlides; Rebecca Lamb; Sharon Sneddon; Anthony Howell; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2012-11-21       Impact factor: 4.534

Review 9.  Understanding the Warburg effect: the metabolic requirements of cell proliferation.

Authors:  Matthew G Vander Heiden; Lewis C Cantley; Craig B Thompson
Journal:  Science       Date:  2009-05-22       Impact factor: 47.728

10.  THE METABOLISM OF TUMORS IN THE BODY.

Authors:  O Warburg; F Wind; E Negelein
Journal:  J Gen Physiol       Date:  1927-03-07       Impact factor: 4.086

View more
  3 in total

Review 1.  Metabolic Regulation of Fibroblast Activation and Proliferation during Organ Fibrosis.

Authors:  Sudan Wang; Yan Liang; Chunsun Dai
Journal:  Kidney Dis (Basel)       Date:  2022-03-03

2.  Biglycan Promotes Cancer Stem Cell Properties, NFκB Signaling and Metastatic Potential in Breast Cancer Cells.

Authors:  Kanakaraju Manupati; Ritama Paul; Mingang Hao; Michael Haas; Zhaoqun Christine Bian; Tammy M Holm; Jun-Lin Guan; Syn Kok Yeo
Journal:  Cancers (Basel)       Date:  2022-01-17       Impact factor: 6.639

3.  Bioactive cationic peptides as potential agents for breast cancer treatment.

Authors:  Marcela Manrique-Moreno; Gloria A Santa-González; Vanessa Gallego
Journal:  Biosci Rep       Date:  2021-12-22       Impact factor: 3.840

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.